Granted Patent
B2
US 12,226,552 · App. 17/038,171 · Granted Feb 18, 2025
Active agent depots formed in situ
Assignee:
Surmodics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Embodiments herein relate to active agent depots formed in situ and related methods. In various embodiments, a method of forming an active agent depot in situ is included. The method can include contacting a composition with a vessel wall, wherein the composition includes an active agent and a fibrin promoting vessel wall transfer agent wherein the ratio of active agent to fibrin promoting vessel wall transfer agent (wt./wt.) is at least 5:1. The method also includes transferring the composition from a device surface to the vessel wall surface. The method also includes forming a fibrin matrix around the composition. Other embodiments are also included herein.
Claims (24)
1. A method of forming an active agent releasing depot in situ comprising
contacting a layer of a composition with a vessel wall;
wherein the composition comprises
a first gradient layer comprising a first active agent;
a second gradient layer comprising the first active agent and a second active agent, wherein the first gradient layer is disposed over the second gradient layer; and
a third gradient layer comprising the first active agent and a third active agent, wherein the second gradient layer is disposed over the third gradient layer;
wherein the first gradient layer, the second gradient layer, and the third gradient layer all comprise a fibrin promoting vessel wall transfer agent;
wherein the composition has an increasing concentration gradient of the first active agent from the first gradient layer to the third gradient layer;
transferring the layer of the composition from a device surface to the vessel wall surface; and
forming an initial fibrin matrix around the composition.
2. The method of claim 1 , wherein the fibrin promoting vessel wall transfer agent is a polyvinylamine (PVAm).
3. The method of claim 1 , wherein the fibrin promoting vessel wall transfer agent is a charged transfer agent.
4. The method of claim 1 , wherein the fibrin promoting vessel wall transfer agent is a cationic agent.
5. The method of claim 1 , wherein the fibrin promoting vessel wall transfer agent is a polycationic agent.
6. The method of claim 1 , wherein the fibrin promoting vessel wall transfer agent is polyethyleneimine.
7. The method of claim 1 , the first active agent comprising sirolimus.
8. The method of claim 1 , the fibrin matrix comprising autologous fibrin.
9. The method of claim 1 , the fibrin matrix comprising exogenous fibrin.
10. The method of claim 1 , the composition further comprising extracellular matrix.
11. The method of claim 1 , the composition further comprising a blood glycoprotein.
12. The method of claim 11 , the blood glycoprotein comprising Von Willebrand factor.
13. The method of claim 1 , the composition further comprising at least one of fibrin or fibrinogen.
14. The method of claim 1 , the composition further comprising at least one clotting factor selected from the group consisting of clotting factor I to XIII.
15. The method of claim 1 , wherein the fibrin matrix is remodeled over time to proteoglycan or other extracellular matrix with or without cells.
Assignments (3)
RELEASE OF SECURITY INTEREST
Recorded Nov 24, 2025
From: MIDCAP FUNDING IV TRUST
To: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
Reel/Frame 073690/0186 →
SECURITY INTEREST
Recorded Aug 23, 2024
From: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 068762/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 27, 2021
From: SLAGER, JORAM
To: SURMODICS, INC.
Reel/Frame 057311/0017 →
Continuity (2)
Provisional Application
62908236
· Sep 30, 2019
References Cited (400)
US 3389099A
· Dressler et al.
· 1968
[cited by applicant]
US 3936391A
· Gabby et al.
· 1976
[cited by applicant]
US 4195637A
· Gruntzig et al.
· 1980
[cited by applicant]
US 4456627A
· Van Heteren
· 1984
[cited by applicant]
US 4490421A
· Levy
· 1984
[cited by applicant]
US 4638045A
· Kohn et al.
· 1987
[cited by applicant]
US 4722906A
· Guire
· 1988
[cited by applicant]
US 4973493A
· Guire
· 1990
[cited by applicant]
US 4973993A
· Allen
· 1990
[cited by applicant]
US 4979959A
· Guire
· 1990
[cited by applicant]
US 5002582A
· Guire et al.
· 1991
[cited by applicant]
US 5041089A
· Mueller et al.
· 1991
[cited by applicant]
US 5073641A
· Bundgaard et al.
· 1991
[cited by applicant]
US 5087246A
· Smith
· 1992
[cited by applicant]
US 5102402A
· Dror et al.
· 1992
[cited by applicant]
US 5201753A
· Lampropoulos et al.
· 1993
[cited by applicant]
US 5263992A
· Guire
· 1993
[cited by applicant]
US 5297607A
· Beauchamp
· 1994
[cited by applicant]
US 5304121A
· Sahatjian
· 1994
[cited by applicant]
US 5318587A
· Davey
· 1994
[cited by applicant]
US 5334146A
· Ozasa
· 1994
[cited by applicant]
US 5382234A
· Cornelius et al.
· 1995
[cited by applicant]
US 5397307A
· Goodin
· 1995
[cited by applicant]
US 5414075A
· Swan et al.
· 1995
[cited by applicant]
US 5466719A
· Jakobson et al.
· 1995
[cited by applicant]
US 5502219A
· Harris
· 1996
[cited by applicant]
US 5512329A
· Guire et al.
· 1996
[cited by applicant]
US 5556383A
· Wang et al.
· 1996
[cited by applicant]
US 5558642A
· Schweich, Jr. et al.
· 1996
[cited by applicant]
US 5571089A
· Crocker
· 1996
[cited by applicant]
US 5585506A
· Harvey
· 1996
[cited by applicant]
US 5616608A
· Kinsella et al.
· 1997
[cited by applicant]
US 5632773A
· Graham et al.
· 1997
[cited by applicant]
US 5637460A
· Swan et al.
· 1997
[cited by applicant]
US 5714360A
· Swan et al.
· 1998
[cited by applicant]
US 5728732A
· Corey
· 1998
[cited by applicant]
US 5741551A
· Guire et al.
· 1998
[cited by applicant]
US 5776101A
· Goy
· 1998
[cited by applicant]
US 5807331A
· Den Heijer et al.
· 1998
[cited by applicant]
US 5811447A
· Kunz et al.
· 1998
[cited by applicant]
US 5833657A
· Reinhardt et al.
· 1998
[cited by applicant]
US 5858653A
· Duran et al.
· 1999
[cited by applicant]
US 5882336A
· Janacek
· 1999
[cited by applicant]
US 5891451A
· Guerrero et al.
· 1999
[cited by applicant]
US 5980948A
· Goedemoed et al.
· 1999
[cited by applicant]
US 6007833A
· Chudzik et al.
· 1999
[cited by applicant]
US 6077698A
· Swan et al.
· 2000
[cited by applicant]
US 6168748B1
· Wang et al.
· 2001
[cited by applicant]
US 6177522B1
· Brady et al.
· 2001
[cited by applicant]
US 6210364B1
· Anderson et al.
· 2001
[cited by applicant]
US 6278018B1
· Swan
· 2001
[cited by applicant]
US 6299604B1
· Ragheb et al.
· 2001
[cited by applicant]
US 6328710B1
· Wang et al.
· 2001
[cited by applicant]
US 6340465B1
· Hsu et al.
· 2002
[cited by applicant]
US 6394995B1
· Solar et al.
· 2002
[cited by applicant]
US 6436440B1
· Meffert et al.
· 2002
[cited by applicant]
US 6444324B1
· Sjoquist et al.
· 2002
[cited by applicant]
US 6465178B2
· Chappa et al.
· 2002
[cited by applicant]
US 6482348B1
· Wang et al.
· 2002
[cited by applicant]
US 6506411B2
· Hunter et al.
· 2003
[cited by applicant]
US 6506895B2
· Guire et al.
· 2003
[cited by applicant]
US 6514734B1
· Clapper et al.
· 2003
[cited by applicant]
US 6515009B1
· Kunz et al.
· 2003
[cited by applicant]
US 6517515B1
· Eidenschink
· 2003
[cited by applicant]
US 6544544B2
· Hunter et al.
· 2003
[cited by applicant]
US 6603040B1
· Swan
· 2003
[cited by applicant]
US 6613066B1
· Fukaya et al.
· 2003
[cited by applicant]
US 6620904B2
· Lemke
· 2003
[cited by applicant]
US 6623452B2
· Chien et al.
· 2003
[cited by applicant]
US 6623504B2
· Vrba et al.
· 2003
[cited by applicant]
US 6663662B2
· Pacetti et al.
· 2003
[cited by applicant]
US 6703040B2
· Katsarava et al.
· 2004
[cited by applicant]
US 6730064B2
· Ragheb et al.
· 2004
[cited by applicant]
US 6762019B2
· Swan et al.
· 2004
[cited by applicant]
US 6896842B1
· Hamilton et al.
· 2005
[cited by applicant]
US 7034765B2
· Fischer et al.
· 2006
[cited by applicant]
US 7138541B2
· Swan
· 2006
[cited by applicant]
US 7163523B2
· Devens, Jr. et al.
· 2007
[cited by applicant]
US 7309593B2
· Ofstead et al.
· 2007
[cited by applicant]
US 7348055B2
· Chappa et al.
· 2008
[cited by applicant]
US 7438710B2
· Anderson et al.
· 2008
[cited by applicant]
US 7507469B2
· Yao et al.
· 2009
[cited by applicant]
US 7696259B2
· Hanley et al.
· 2010
[cited by applicant]
US 7731685B2
· Schaeffer et al.
· 2010
[cited by applicant]
US 7736689B2
· Chappa et al.
· 2010
[cited by applicant]
US 7758892B1
· Chen et al.
· 2010
[cited by applicant]
US 7772393B2
· Guire et al.
· 2010
[cited by applicant]
US 7797033B2
· D'Andrea et al.
· 2010
[cited by applicant]
US 7803149B2
· Schaeffer et al.
· 2010
[cited by applicant]
US 7807750B2
· Taton et al.
· 2010
[cited by applicant]
US 7820193B2
· Hunter et al.
· 2010
[cited by applicant]
US 7850727B2
· Shanley et al.
· 2010
[cited by applicant]
US 8034765B2
· De et al.
· 2011
[cited by applicant]
US 8039524B2
· Ralph et al.
· 2011
[cited by applicant]
US 8158106B2
· Guire et al.
· 2012
[cited by applicant]
US 8172793B2
· Choules et al.
· 2012
[cited by applicant]
US 8202530B2
· Hossainy et al.
· 2012
[cited by applicant]
US 8246576B2
· Slager
· 2012
[cited by applicant]
US 8257305B2
· Scheller et al.
· 2012
[cited by applicant]
US 8293262B2
· Chen et al.
· 2012
[cited by applicant]
US 8439868B2
· Scheller et al.
· 2013
[cited by applicant]
US 8469943B2
· Bates et al.
· 2013
[cited by applicant]
US 8487137B2
· Guire et al.
· 2013
[cited by applicant]
US 8513320B2
· Rooijmans
· 2013
[cited by applicant]
US 8557272B2
· Zhao et al.
· 2013
[cited by applicant]
US 8663674B2
· Wen et al.
· 2014
[cited by applicant]
US 8673387B2
· Bates et al.
· 2014
[cited by applicant]
US 8697112B2
· Ditizio et al.
· 2014
[cited by applicant]
US 8809411B2
· Rooijmans
· 2014
[cited by applicant]
US 8871819B2
· Meyering et al.
· 2014
[cited by applicant]
US 8889760B2
· Kurdyumov et al.
· 2014
[cited by applicant]
US 8952103B2
· Blondel et al.
· 2015
[cited by applicant]
US 9375517B2
· Babcock
· 2016
[cited by applicant]
US 9555119B2
· Ventura et al.
· 2017
[cited by applicant]
US 9757497B2
· Slager
· 2017
[cited by applicant]
US 9782516B2
· Pacetti et al.
· 2017
[cited by applicant]
US 9861727B2
· Slager et al.
· 2018
[cited by applicant]
US 9999675B2
· Ventura et al.
· 2018
[cited by applicant]
US 20020006493A1
· Chabrecek et al.
· 2002
[cited by applicant]
US 20020082680A1
· Shanley
· 2002
[cited by examiner]
US 20020123801A1
· Pacetti et al.
· 2002
[cited by applicant]
US 20030065355A1
· Weber
· 2003
[cited by applicant]
US 20030195611A1
· Greenhalgh et al.
· 2003
[cited by applicant]
US 20030211135A1
· Greenhalgh et al.
· 2003
[cited by applicant]
US 20040044404A1
· Stucke et al.
· 2004
[cited by applicant]
US 20040051201A1
· Greenhalgh et al.
· 2004
[cited by applicant]
US 20040105839A1
· Park
· 2004
[cited by applicant]
US 20040117007A1
· Whitbourne et al.
· 2004
[cited by applicant]
US 20050100580A1
· Osborne et al.
· 2005
[cited by applicant]
US 20050187605A1
· Greenhalgh et al.
· 2005
[cited by applicant]
US 20050255142A1
· Chudzik et al.
· 2005
[cited by applicant]
US 20050281857A1
· Heyer et al.
· 2005
[cited by applicant]
US 20060018948A1
· Guire et al.
· 2006
[cited by applicant]
US 20060020243A1
· Speck et al.
· 2006
[cited by applicant]
US 20060030669A1
· Taton et al.
· 2006
[cited by applicant]
US 20060148982A1
· Uchegbu et al.
· 2006
[cited by applicant]
US 20060200232A1
· Phaneuf et al.
· 2006
[cited by applicant]
US 20060240194A1
· Lemke et al.
· 2006
[cited by applicant]
US 20070026037A1
· Kloke et al.
· 2007
[cited by applicant]
US 20070032882A1
· Lodhi et al.
· 2007
[cited by applicant]
US 20070048351A1
· Lunn
· 2007
[cited by applicant]
US 20070065481A1
· Chudzik et al.
· 2007
[cited by applicant]
US 20070128343A1
· Chappa
· 2007
[cited by examiner]
US 20070154591A1
· Andersen
· 2007
[cited by applicant]
US 20070155906A1
· Hissink et al.
· 2007
[cited by applicant]
US 20070218102A1
· Chudzik et al.
· 2007
[cited by applicant]
US 20070224247A1
· Chudzik et al.
· 2007
[cited by applicant]
US 20070260054A1
· Chudzik
· 2007
[cited by applicant]
US 20080020013A1
· Reyes et al.
· 2008
[cited by applicant]
US 20080220054A1
· Shastri et al.
· 2008
[cited by applicant]
US 20080233183A1
· McCook et al.
· 2008
[cited by applicant]
US 20090030504A1
· Weber et al.
· 2009
[cited by applicant]
US 20090043276A1
· Weber et al.
· 2009
[cited by applicant]
US 20090043378A1
· Cheng et al.
· 2009
[cited by applicant]
US 20090081276A1
· Alsberg et al.
· 2009
[cited by applicant]
US 20090221767A1
· Malet
· 2009
[cited by applicant]
US 20090226501A1
· Parsonage et al.
· 2009
[cited by applicant]
US 20090227946A1
· Kangas
· 2009
[cited by applicant]
US 20100015240A1
· Biggs
· 2010
[cited by applicant]
US 20100040766A1
· Chappa et al.
· 2010
[cited by applicant]
US 20100076377A1
· Ehrenreich et al.
· 2010
[cited by applicant]
US 20100076401A1
· Von et al.
· 2010
[cited by applicant]
US 20100087783A1
· Weber et al.
· 2010
[cited by applicant]
US 20100096320A1
· Opperman et al.
· 2010
[cited by applicant]
US 20100130837A1
· Matott
· 2010
[cited by applicant]
US 20100198168A1
· Rooijmans
· 2010
[cited by applicant]
US 20100272774A1
· Chappa
· 2010
[cited by applicant]
US 20100274012A1
· Guire et al.
· 2010
[cited by applicant]
US 20100292668A1
· Slager
· 2010
[cited by applicant]
US 20110008260A1
· Flanagan et al.
· 2011
[cited by applicant]
US 20110022027A1
· Morishita et al.
· 2011
[cited by applicant]
US 20110046255A1
· Rooijmans
· 2011
[cited by applicant]
US 20110059874A1
· Rooijmans et al.
· 2011
[cited by applicant]
US 20110092919A1
· Pierce
· 2011
[cited by examiner]
US 20110144373A1
· Swan et al.
· 2011
[cited by applicant]
US 20110245367A1
· Kurdyumov et al.
· 2011
[cited by applicant]
US 20110250255A1
· Parsonage et al.
· 2011
[cited by applicant]
US 20110257339A1
· Fischer et al.
· 2011
[cited by applicant]
US 20110275725A1
· Meyering et al.
· 2011
[cited by applicant]
US 20120039983A1
· Uhrich et al.
· 2012
[cited by applicant]
US 20120046384A2
· Kurdyumov et al.
· 2012
[cited by applicant]
US 20120083734A1
· Ayres et al.
· 2012
[cited by applicant]
US 20120148852A1
· Jelle et al.
· 2012
[cited by applicant]
US 20120149934A1
· Kurdyumov
· 2012
[cited by applicant]
US 20120177742A1
· McClain et al.
· 2012
[cited by applicant]
US 20120177910A1
· Weber et al.
· 2012
[cited by applicant]
US 20120296274A1
· Slager
· 2012
[cited by applicant]
US 20130143056A1
· Swan et al.
· 2013
[cited by applicant]
US 20130190689A1
· Slager
· 2013
[cited by applicant]
US 20130197433A1
· Babcock
· 2013
[cited by applicant]
US 20130302529A1
· Kurdyumov
· 2013
[cited by applicant]
US 20140004158A1
· McGonigle
· 2014
[cited by applicant]
US 20140142166A1
· Ventura
· 2014
[cited by applicant]
US 20140162083A1
· Kurdyumov et al.
· 2014
[cited by applicant]
US 20140193474A1
· Babcock et al.
· 2014
[cited by applicant]
US 20140276636A1
· Lee et al.
· 2014
[cited by applicant]
US 20140277399A1
· Pacetti
· 2014
[cited by examiner]
US 20140336571A1
· Slager
· 2014
[cited by applicant]
US 20150140107A1
· Slager
· 2015
[cited by examiner]
US 20150283092A1
· Ruddy et al.
· 2015
[cited by applicant]
US 20170072057A1
· Ventura et al.
· 2017
[cited by applicant]
US 20170112973A1
· Slager et al.
· 2017
[cited by applicant]
US 20180110903A1
· Slager et al.
· 2018
[cited by applicant]
US 20180169032A1
· Kloke
· 2018
[cited by applicant]
US 20180272040A1
· Chappa et al.
· 2018
[cited by applicant]
US 20190290804A1
· Askari
· 2019
[cited by examiner]
US 20200237971A1
· Slager et al.
· 2020
[cited by applicant]
CA 2836266
· 2012
[cited by applicant]
CA 2890205
· 2014
[cited by applicant]
CN 1413118
· 2003
[cited by applicant]
CN 1950114
· 2007
[cited by applicant]
CN 1964750
· 2007
[cited by applicant]
CN 102036696
· 2011
[cited by applicant]
EP 0882461
· 1998
[cited by applicant]
EP 1176993
· 2003
[cited by applicant]
EP 1430917
· 2004
[cited by applicant]
EP 1994950
· 2008
[cited by applicant]
EP 1997525
· 2008
[cited by applicant]
EP 2019695
· 2009
[cited by applicant]
EP 2251050
· 2010
[cited by applicant]
EP 2098230
· 2012
[cited by applicant]
EP 2292225
· 2012
[cited by applicant]
JP 10328293
· 1998
[cited by applicant]
JP H11322586
· 1999
[cited by applicant]
JP 2003506417
· 2003
[cited by applicant]
JP 2006500437
· 2006
[cited by applicant]
JP 2006508912
· 2006
[cited by applicant]
JP 2007537005
· 2007
[cited by applicant]
JP 2008519771
· 2008
[cited by applicant]
JP 2009502243
· 2009
[cited by applicant]
WO 9964086
· 1999
[cited by applicant]
WO 0110468
· 2001
[cited by applicant]
WO 2001045742
· 2001
[cited by applicant]
WO 03055611
· 2003
[cited by applicant]
WO 2004017943
· 2004
[cited by applicant]
WO 2005079754
· 2005
[cited by applicant]
WO 2005113034
· 2005
[cited by applicant]
WO 2006019848
· 2006
[cited by applicant]
WO 2006026187
· 2006
[cited by applicant]
WO 2006053175
· 2006
[cited by applicant]
WO 2007012051
· 2007
[cited by applicant]
WO 2007106441
· 2007
[cited by applicant]
WO 2007136504
· 2007
[cited by applicant]
WO 2009051614
· 2009
[cited by applicant]
WO 2009113605
· 2009
[cited by applicant]
WO 2009121629
· 2009
[cited by applicant]
WO 2010111517
· 2010
[cited by applicant]
WO 2010129328
· 2010
[cited by applicant]
WO 2011005421
· 2011
[cited by applicant]
WO 2011024831
· 2011
[cited by applicant]
WO 2011052089
· 2011
[cited by applicant]
WO 2011143237
· 2011
[cited by applicant]
WO 2012003293
· 2012
[cited by applicant]
WO 2012162061
· 2012
[cited by applicant]
WO 2013109930
· 2013
[cited by applicant]
WO 2013169879
· 2013
[cited by applicant]
WO 2014071387
· 2014
[cited by applicant]
WO 2014186729
· 2014
[cited by applicant]
WO 2016123480
· 2016
[cited by applicant]
WO 2018118671
· 2018
[cited by applicant]
Akiyama, Yohko et al., “In Vitro and in Vivo evaluation of Mucoadhesive Microspheres Prepared for the Gastrointestinal Tract Using Polyglycerol Esters of Fatty Acids and a Poly(acrylic acid) Derivative,” Pharmaceutical …
[cited by applicant]
Avella, “Addition of glycerol plasticizer to seaweeds derived alginates: Influences of microstructure on chemical-physical properties,” Carbohydrate Polymers vol. 69, Issue 3, Jun. 25, 2007, 503-511.
[cited by applicant]
Babayan, V K. “Preparation and Properties of Some Polyglycerol Esters of Short and Medium Length Fatty Acids,” Journal of the American Oil Chemists' Society Jul. 1971 Jul. 1971, 307-309.
[cited by applicant]
Babayan, V K et al., “Nutritional Studies of Polyglycerol Esters,” The Journal of the American Oil Chemist' Society vol. 41, Jun. 1964 Jun. 1964, 434-438.
[cited by applicant]
Birnbaum, Duane T. et al., “Microparticle Drug Delivery Systems,” Chapter 6, Drug Delivery Systems in Cancer Therapy, 2003, (pp. 117-135).
[cited by applicant]
Bodansky, M et al., “Utilization of Polyglycerol Esters,” Biochemistry vol. 32 Aug. 30, 1938, 1938-1942.
[cited by applicant]
Brunot, Celine et al., “Cytoxicity of Polyethyleneimine (PEI), Precursor Base Layer of Polyelectrolyte Multilayer Films,” Biomaterials, 2007. 28(4): p. 632-40 (9 pages).
[cited by applicant]
Byrne, Robert A. “Drug-Coated Balloon Therapy in Coronary and Peripheral Artery Disease,” Nat Rev Cardiol, 2014. 11(1): p. 13-23 (11 pages).
[cited by applicant]
Chaabane, Chiraz “Biological Responses in Stented Arteries,” Cardiovasc Res, 2013. 99(2): p. 353-63 (11 pages).
[cited by applicant]
Charlemagne, D et al., “Enzymatic Synthesis of Polyglycerol-Fatty Acid Esters in a Solvent-Free System,” Journal for American Oil Chemists' Society vol. 72. No. 1 (1995) 1995, 61-65.
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” For European Application No. 10716714, mailed on Feb. 13, 2015 (6 pages).
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Application No. 10716714, mailed on Jan. 18, 2013 (5 pages).
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Application No. 13792207.6, mailed Sep. 29, 2017 (5 pages).
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 12723063.9 mailed Jan. 16, 2019 (5 pages).
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 12723063.9 mailed Jun. 12, 2017 (5 pages).
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 14730381.2 mailed Nov. 21, 2017 (4 pages).
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 16703247.3 mailed Apr. 23, 2019 (5 pages).
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 16703247.3 mailed Feb. 12, 2020 (7 pages).
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 16703247.3 mailed Sep. 4, 2018 (5 pages).
[cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 17835893.3 mailed Jun. 29, 2020 (5 pages).
[cited by applicant]
De Meulenaer, B et al., “Development of Chromatographic Method for the Determination of Degree of Polymerisation of Polyglycerols and Polyglycerol Fatty Acid Esters,” Chromatographia vol. 51, No. 1/2, Jan. 2000 Jan. 200…
[cited by applicant]
“Decision of Refusal,” for Japanese Patent Application No. 2012-508637, mailed Feb. 3, 2015 (3 pages) with English summary.
[cited by applicant]
“Decision of Rejection,” for Chinese Patent Application No. 201510411761.0 mailed Nov. 30, 2018 (19 pages) with English Translation.
[cited by applicant]
Dobson, Kevin S. et al., “The Preparation of Polyglycerol Esters Suitable as Low-Caloric Fat Substitutes,” Journal of The American Oil Chemists' Society vol. 70, No. 11 (Nov. 1993) Nov. 1993, 1089-1092.
[cited by applicant]
Dow Corning Corp., “A guide to Silane Solutions,” 2005 (30 pages).
[cited by applicant]
FAO Nutrition Meetings Report, “Toxicological Evaluation Of Some Antimicrobials, Antioxidants, Emulsifiers, Stabilizers, Flour-treatment Agents, Acids And Bases,” FAO Nutrition Meetings Report Series No. 40a, B, C Who/ …
[cited by applicant]
“File History,” for U.S. Appl. No. 12/769,127, retrieved Apr. 7, 2021 (487 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 13/469,844, retrieved Apr. 7, 2021 (395 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 13/793,390 retrieved Apr. 7, 2021 (371 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 14/072,520, retrieved Apr. 7, 2021 (192 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 14/280,170 retrieved Apr. 12, 2021 (669 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 14/609,270, retrieved Apr. 12, 2021 (343 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 15/357,496 retrieved Apr. 12, 2021 (149 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 15/385,112, retrieved Apr. 19, 2021 (252 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 15/840,540, retrieved Apr. 19, 2021 (304 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 15/850,010 retrieved Apr. 19, 2021 (223 pages).
[cited by applicant]
“File History,” for U.S. Appl. No. 15/994,263 retrieved Apr. 19, 2021 (199 pages).
[cited by applicant]
“Final Rejection,” from CN Application No. 201080018767.7, mailed Jan. 6, 2014 (10 pages).
[cited by applicant]
Finkel, Toren “Relief with Rapamycin: mTOR Inhibition Protects Against Radiation-Induced Mucositis,” Cell Stem Cell, vol. 11:3, Sep. 7, 2012 (pp. 1-4).
[cited by applicant]
“First Examination Report,” for Indian Patent Application No. 201747029823 mailed Nov. 25, 2019 (6 pages).
[cited by applicant]
“First Examination Report,” for Indian Patent Application No. 3723/KOLNP/2013 mailed Sep. 28, 2018 (5 pages).
[cited by applicant]
“First Office Action,” for Chinese Application No. 201080018767.7 mailed Jun. 8, 2013 (9 pages).
[cited by applicant]
“First Office Action,” for Chinese Patent Application No. 2012800328049, mailed Mar. 2, 2015 (12 pages) including English translation.
[cited by applicant]
“First Office Action,” for Chinese Patent Application No. 201510411761.0 mailed Jun. 30, 2017 (13 pages) with English translation.
[cited by applicant]
“First Office Action,” for Chinese Patent Application No. 2016800187265 mailed Nov. 5, 2019 (9 pages) with English Translation.
[cited by applicant]
“First Office Action,” for Russian Patent Application No. 2017129933 mailed Jun. 27, 2019 (10 pages) with English Translation.
[cited by applicant]
“Fourth Office Action,” for Chinese Patent Application No. 2012800328049, mailed May 3, 2017 (8 pages) with English translation.
[cited by applicant]
From Wikipedia, “Electrospinning,” From Wikipedia, the free encyclopedia, http://en.wikipedia.org/wiki/Electrospinning, downloaded Sep. 13, 2010; last updated Sep. 2, 2010, 2009, (pp. 1-6).
[cited by applicant]
Ghonaim, Hassan M. et al., “N1, N12-Diacyl Spermines: SAR Studies on Non-viral Lipopolyamine Vectors for Plasmid DNA and siRNA Formulation,” Pharmaceutical Research, vol. 27, No. 1, Jan. 2010 (p. 17-29) Oct. 30, 2009.
[cited by applicant]
Hagemeier, C J. “Ocular Tolerability of Poly(lactide-co-glyoliide) Microspheres Following Subconjunctival and Intravitreal Injection in Rabbit Eyes,” ARVO 2010 Presented ARVO 2010, Hall B/C, May 6, 2010 8:30am-10:15am M…
[cited by applicant]
Howes, D et al., “The Fate of Ingested Glyceran Esters of Condensed Castor Oil Fatty Acids [Polyglycerol Polyricinoleate (PGPR)] in the Rat,” Food and Chemical Toxicology 36 (1998) 719-738 1998, 719-738.
[cited by applicant]
“International Preliminary Report on Patentability,” for PCT Application No. PCT/US2016/015644 mailed Aug. 10, 2017 (12 pages).
[cited by applicant]
“International Preliminary Report on Patentability,” for PCT Application No. PCT/US2017/066573 mailed Jul. 4, 2019 (7 pages).
[cited by applicant]
“International Preliminary Report on Patentability,” for PCT/US2012/038158, mailed Nov. 28, 2013 (8 pages).
[cited by applicant]
“International Preliminary Report on Patentability,” for PCT/US2013/068539, mailed May 14, 2015 (9 pages).
[cited by applicant]
“International Preliminary Report on Patentability,” for PCT/US2014/038435 mailed Nov. 26, 2015 (10 pages).
[cited by applicant]
“International Search Report & Written Opinion,” for PCT/US2016/015644 mailed Jul. 11, 2016 (17 pages).
[cited by applicant]
“International Search Report and Written Opinion,” for PCT Application No. PCT/US2017/066573 mailed Apr. 3, 2018 (10 pages).
[cited by applicant]
“International Search Report and Written Opinion,” for PCT/US2010/032741 mailed Dec. 13, 2010 (11 pages). Dec. 13, 2010, 11 pages.
[cited by applicant]
“International Search Report and Written Opinion,” for PCT/US2012/038158, mailed Sep. 27, 2012 (13 pages).
[cited by applicant]
“International Search Report and Written Opinion,” for PCT/US2013/068539, mailed Jan. 22, 2014 (12 pages).
[cited by applicant]
“International Search Report and Written Opinion,” for PCT/US2014/038435, mailed Aug. 25, 2014 (13 pages).
[cited by applicant]
“Invitation to Pay Additional Fees and Partial Search Report,” for PCT Application No. PCT/US2016/015644, mailed May 3, 2016 (8 pages).
[cited by applicant]
“Invitation to Respond to Written Opinion,” for SG Patent Application No. 201107896-1, mailed Jun. 12, 2012 (6 pages).
[cited by applicant]
Kallinteri, Paraskevi et al., “Novel Functionalized Biodegradable Polymers for Nanoparticle Drug Delivery Systems,” Biomacromolecules 2005 2006, 6, 1885-1894; American Chemical Society Apr. 27, 2005, 1885-1894.
[cited by applicant]
Kumar, Majeti N.V. R. “Nano and Microparticles as Controlled Drug Delivery Devices,” J. Pharm Pharmaceut Sci, 3(2), 2000 (pp. 234-258).
[cited by applicant]
Liu, Rong “Water-Insoluble Drug Formulation,” CRC Press, 2nd Ed., 2008 (pp. 1-3).
[cited by applicant]
Love, Kevin T. et al., “Lipid-Like Materials for Low-Dose In Vivo Gene Silencing,” PNAS Feb. 2010, 107 (5) 1864-1869, www.pnas.org/cgi/doi/10.1073/pnas.0910603106 (6 pages).
[cited by applicant]
McIntyre, R T. “Polyglycerol esters,” Journal of American Oil Chemists' Society Nov. 1979 (vol. 56) Nov. 1979, 835A-840A.
[cited by applicant]
Mugabe, Clement et al., “Paclitaxel Incorporated in Hydrophobically Derivatized Hyperbranched Polyglycerols for Intravesical Bladder Cancer Therapy,” BJU International, 2008, vol. 103, p. 978-986.
[cited by applicant]
“Non-Final Office Action,” for Japanese Patent Application No. 2012-508637, mailed Mar. 18, 2014 (4 pages) with English translation.
[cited by applicant]
“Non-Final Office Action,” for Mexican Patent Application No. MX/a/2011/011389, mailed Aug. 18, 2015 (1 page).
[cited by applicant]
“Non-Final Office Action,” for Mexican Patent Application No. MX/a/2011/011389, mailed Feb. 22, 2016 (1 page).
[cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 16/847,272 mailed Jan. 7, 2021 (36 pages).
[cited by applicant]
“Notification for Patent Reexamination,” for Chinese Patent Application No. 201080018767.7, mailed Sep. 25, 2014 (12 pages) with English translation.
[cited by applicant]
“Office Action Response,” for Israeli Patent Application No. 242545 filed Sep. 28, 2019 (133 pages) English Translation.
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,760,187 mailed Jan. 12, 2017 (3 pages).
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,760,187 mailed Mar. 24, 2016 (4 pages).
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,836,266 mailed Apr. 11, 2018 (3 pages).
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,836,266 mailed Jul. 23, 2020 (3 pages).
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,836,266 mailed Nov. 30, 2018 (4 pages).
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,836,266 mailed Oct. 23, 2019 (3 pages).
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,890,205 mailed Sep. 18, 2019 (5 pages).
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,912,690 mailed Apr. 29, 2020 (5 pages).
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,912,690 mailed Feb. 23, 2021 (3 pages).
[cited by applicant]
“Office Action,” for Canadian Patent Application No. 2,912,690 mailed Nov. 5, 2020 (3 pages).
[cited by applicant]
“Office Action,” for Israeli Patent Application No. 242545 mailed Feb. 6, 2020 (7 pages) with English Translation.
[cited by applicant]
“Office Action,” for Israeli Patent Application No. 242545 mailed May 28, 2019 (8 pages) with English Translation.
[cited by applicant]
“Office Action,” for Israeli Patent Application No. 253612 mailed Jul. 31, 2020 (8 pages) with English Translation.
[cited by applicant]
“Office Action,” for Japanese Patent Application No. 2014511494 mailed Feb. 5, 2016 (13 pages) with English Translation.
[cited by applicant]
“Office Action,” for Japanese Patent Application No. 2014511494 mailed Nov. 25, 2016 (6 pages) with English Translation.
[cited by applicant]
“Office Action,” for Japanese Patent Application No. 2015-540868 mailed Aug. 31, 2017 (10 pages) with English translation.
[cited by applicant]
“Office Action,” for Japanese Patent Application No. 2015-540868 mailed May 21, 2018 (6 pages) with English translation.
[cited by applicant]
“Office Action,” for Japanese Patent Application No. 2016-514136 mailed Apr. 10, 2018 (7 pages) with English translation.
[cited by applicant]
“Office Action,” for Japanese Patent Application No. 2017-540169 mailed Jul. 30, 2020 (9 pages) with English Translation.
[cited by applicant]
“Office Action,” for Japanese Patent Application No. 2017-540169 mailed Nov. 21, 2019 (12 pages) with English Translation.
[cited by applicant]
“Office Action,” for Mexican Patent Application No. MX/a/2015/015589 mailed Sep. 9, 2018 (1 page), translation only.
[cited by applicant]
“Office Action,” for Mexican Patent Application No. MX/a/2017/009688 mailed Dec. 10, 2020 (6 pages) with English Translation.
[cited by applicant]
“Office Action,” for Mexican Patent Application No. MX/a/2017/009688 mailed Jul. 14, 2020 (5 pages) with English Translation.
[cited by applicant]
“Office Action,” for Russian Patent Application No. 2017129933 mailed Mar. 2, 2020 (9 pages) with English Translation.
[cited by applicant]
“Office Action,” for Russian Patent Application No. 2017129933 mailed Oct. 21, 2019 (9 pages) with English Translation.
[cited by applicant]
Ong, B.C. et al., “Interparticle Forces in Spherical Monodispersed Silica Dispersions: Effects of Branched Polyethylenimine and Molecular Weight,” Journal of Colloid and Interface Science, 2009. 337(1): p. 24-31 (8 page…
[cited by applicant]
Orafei, Hossein et al., “Novel Poly(glycerol-adipate) Polymers Used for Nanoparticle Making: A Study of Surface Free Energy,” Iranian Journal of Pharmaceutical Research (2008), 7 (1): 11-19 2008, 11-19.
[cited by applicant]
“PCT Notification Concerning Transmittal of Copy of International Preliminary Report on Patentability,” from International Application No. PCT/US10/032741, mailed Nov. 10, 2011, pp. 1-8, 8.
[cited by applicant]
“Preliminary Office Action,” for Brazilian Patent Application No. 1120170136420 mailed Oct. 15, 2019 (7 pages) with English Translation.
[cited by applicant]
“Product Data Sheet,” for PEBAX MV 1074 SA 01 MED from Arkema (2013, pp. 1-2) 2 pages.
[cited by applicant]
Puri, Sanyogita “Drug Incorporation and Release of Water Soluble Drugs from Novel Functionalized Poly(glycerol adipate) Nanoparticles,” Journal of Controlled Release 125 (2008) Oct. 10, 2007, 59-67.
[cited by applicant]
“Reexamination Notification,” for Chinese Patent Application No. 201510411761.0 mailed Jun. 3, 2020 (13 pages) with English Translation.
[cited by applicant]
Renkin, Eugene M. “Filtration, Diffusion, and Molecular Sieving Through Porous Cellulose Membranes,” Nov. 20, 1954 (pp. 1-19).
[cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC,” for European Application No. 10716714.0 filed with EPO Aug. 11, 2015 (51 pages).
[cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC,” for European Application No. 10716714.0 filed with EPO Jun. 10, 2013 (9 pages).
[cited by applicant]
“Response to communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 12723063.9 filed Jul. 2, 2019 (56 pages).
[cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 12723063.9 filed with the EPO Nov. 16, 2017 (9 pages).
[cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 13792207.6, filed with the EPO Mar. 29, 2018 (25 pages).
[cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC, ” for European Patent Application No. 14730381.2, filed with the European Patent Office Dec. 21, 2017 (68 pages).
[cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 16703247.3 filed Aug. 11, 2020 (10 pages).
[cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 16703247.3 filed Aug. 30, 2019 (10 pages).
[cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 16703247.3 filed Dec. 20, 2018 (7 pages).
[cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 17835893.3 filed Oct. 29, 2020 (7 pages).
[cited by applicant]
“Response to Communication Pursuant to Rule 161 and 162 EPC,” for European Patent Application 12723063.9, mailed Jan. 21, 2014 and filed with the EPO Jul. 18, 2014 (4 pages).
[cited by applicant]
“Response to Communication Pursuant to Rules 161(1) and 162 EPC,” for European Application No. 13792207.6, filed with the EPO Feb. 3, 2016 (4 pages).
[cited by applicant]
“Response to Communication Pursuant to Rules 161(1) and 162 EPC,” for European Patent Application No. 14730381.2, filed with the European Patent Office Jul. 14, 2016 (14 pages).
[cited by applicant]
“Response to Communication Pursuant to Rules 161(1) and 162 EPC,” for European Patent Application No. 17835893.3 filed Jan. 21, 2020 (7 pages).
[cited by applicant]
“Response to Communication Pursuant to Rules 161(1) and 162 EPC,” for European Patent No. 16703247.3 filed with the EPO on Mar. 22, 2018.
[cited by applicant]
“Response to First Examination Report,” for Indian Patent Application No. 201747029823 filed May 22, 2020 (13 pages).
[cited by applicant]
“Response to First Examination Report,” for Indian Patent Application No. 3723/KOLNP/2013 filed Feb. 20, 2019 (23 pages).
[cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 2,760,187 filed with CIPO Feb. 15, 2017 (5 pages).
[cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 2,760,187 filed with CIPO Sep. 22, 2016 (22 pages).
[cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 2,836,266 filed Apr. 15, 2020 (18 pages).
[cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 2,836,266 filed May 29, 2019 (19 pages).
[cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 2,836,266 filed Oct. 19, 2020 (8 pages).
[cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 2,836,266 filed with CIPO Sep. 20, 2018 (28 pages).
[cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 2,890,205 filed Mar. 18, 2020 (28 pages).
[cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 2,912,690 filed Aug. 13, 2020 (39 pages).
[cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 2,912,690 filed Jan. 8, 2021 (21 pages).
[cited by applicant]